Literature DB >> 15897956

Neuroimaging and therapeutics in movement disorders.

Thomas Eckert1, David Eidelberg.   

Abstract

In this review, we discuss the role of neuroimaging in assessing treatment options for movement disorders, particularly Parkinson's disease (PD). Imaging methods to assess dopaminergic function have recently been applied in trials of potential neuroprotective agents. Other imaging methods using regional metabolism and/or cerebral perfusion have been recently introduced to quantify the modulation of network activity as an objective marker of the treatment response. Both imaging strategies have provided novel insights into the mechanisms underlying a variety of pharmacological and stereotaxic surgical treatment strategies for PD and other movement disorders.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15897956      PMCID: PMC1064997          DOI: 10.1602/neurorx.2.2.361

Source DB:  PubMed          Journal:  NeuroRx        ISSN: 1545-5343


  116 in total

1.  Retrospective application of a set of clinical diagnostic criteria for the diagnosis of multiple system atrophy.

Authors:  I Litvan; V Booth; G K Wenning; J J Bartko; C G Goetz; A McKee; J Jankovic; K Jellinger; E C Lai; J P Brandel; M Verny; K R Chaudhuri; R K Pearce; Y Agid
Journal:  J Neural Transm (Vienna)       Date:  1998       Impact factor: 3.575

2.  Differential diagnosis of parkinsonism with [18F]fluorodeoxyglucose and PET.

Authors:  A Antonini; K Kazumata; A Feigin; F Mandel; V Dhawan; C Margouleff; D Eidelberg
Journal:  Mov Disord       Date:  1998-03       Impact factor: 10.338

3.  Early differential diagnosis of Parkinson's disease with 18F-fluorodeoxyglucose and positron emission tomography.

Authors:  D Eidelberg; J R Moeller; T Ishikawa; V Dhawan; P Spetsieris; T Chaly; A Belakhlef; F Mandel; S Przedborski; S Fahn
Journal:  Neurology       Date:  1995-11       Impact factor: 9.910

4.  Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices.

Authors:  B D Pate; T Kawamata; T Yamada; E G McGeer; K A Hewitt; B J Snow; T J Ruth; D B Calne
Journal:  Ann Neurol       Date:  1993-09       Impact factor: 10.422

5.  The metabolic topography of idiopathic torsion dystonia.

Authors:  D Eidelberg; J R Moeller; T Ishikawa; V Dhawan; P Spetsieris; S Przedborski; S Fahn
Journal:  Brain       Date:  1995-12       Impact factor: 13.501

6.  Frequency-dependent changes of regional cerebral blood flow during finger movements.

Authors:  N Sadato; V Ibañez; M P Deiber; G Campbell; M Leonardo; M Hallett
Journal:  J Cereb Blood Flow Metab       Date:  1996-01       Impact factor: 6.200

7.  The metabolic topography of parkinsonism.

Authors:  D Eidelberg; J R Moeller; V Dhawan; P Spetsieris; S Takikawa; T Ishikawa; T Chaly; W Robeson; D Margouleff; S Przedborski
Journal:  J Cereb Blood Flow Metab       Date:  1994-09       Impact factor: 6.200

8.  Effects of levodopa on motor sequence learning in Parkinson's disease.

Authors:  A Feigin; M F Ghilardi; M Carbon; C Edwards; M Fukuda; V Dhawan; C Margouleff; C Ghez; D Eidelberg
Journal:  Neurology       Date:  2003-06-10       Impact factor: 9.910

9.  Assessment of disease severity in parkinsonism with fluorine-18-fluorodeoxyglucose and PET.

Authors:  D Eidelberg; J R Moeller; T Ishikawa; V Dhawan; P Spetsieris; T Chaly; W Robeson; J R Dahl; D Margouleff
Journal:  J Nucl Med       Date:  1995-03       Impact factor: 10.057

10.  Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.

Authors:  A Antonini; P Vontobel; M Psylla; I Günther; P R Maguire; J Missimer; K L Leenders
Journal:  Arch Neurol       Date:  1995-12
View more
  19 in total

1.  Metabolic brain networks associated with cognitive function in Parkinson's disease.

Authors:  Chaorui Huang; Paul Mattis; Chengke Tang; Kenneth Perrine; Maren Carbon; David Eidelberg
Journal:  Neuroimage       Date:  2006-11-17       Impact factor: 6.556

Review 2.  Imaging in cell-based therapy for neurodegenerative diseases.

Authors:  Deniz Kirik; Nathalie Breysse; Tomas Björklund; Laurent Besret; Philippe Hantraye
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-12       Impact factor: 9.236

Review 3.  Single-photon emission computed tomography in neurotherapeutics.

Authors:  Michael D Devous
Journal:  NeuroRx       Date:  2005-04

4.  Abnormal metabolic network activity in Parkinson's disease: test-retest reproducibility.

Authors:  Yilong Ma; Chengke Tang; Phoebe G Spetsieris; Vijay Dhawan; David Eidelberg
Journal:  J Cereb Blood Flow Metab       Date:  2006-06-28       Impact factor: 6.200

Review 5.  The assessment of neurological systems with functional imaging.

Authors:  David Eidelberg
Journal:  Brain Lang       Date:  2006-08-08       Impact factor: 2.381

Review 6.  Assessment of the progression of Parkinson's disease: a metabolic network approach.

Authors:  Thomas Eckert; Chengke Tang; David Eidelberg
Journal:  Lancet Neurol       Date:  2007-10       Impact factor: 44.182

Review 7.  Neuroimaging and transcranial ultrasonography in Parkinson's disease.

Authors:  Shyamal H Mehta; John C Morgan; Kapil D Sethi
Journal:  Curr Neurol Neurosci Rep       Date:  2008-07       Impact factor: 5.081

Review 8.  Metabolic networks for assessment of therapy and diagnosis in Parkinson's disease.

Authors:  Shigeki Hirano; Thomas Eckert; Toni Flanagan; David Eidelberg
Journal:  Mov Disord       Date:  2009       Impact factor: 10.338

9.  Changes in network activity with the progression of Parkinson's disease.

Authors:  Chaorui Huang; Chengke Tang; Andrew Feigin; Martin Lesser; Yilong Ma; Michael Pourfar; Vijay Dhawan; David Eidelberg
Journal:  Brain       Date:  2007-04-30       Impact factor: 13.501

10.  Abnormal regional brain function in Parkinson's disease: truth or fiction?

Authors:  Yilong Ma; Chengke Tang; James R Moeller; David Eidelberg
Journal:  Neuroimage       Date:  2008-10-18       Impact factor: 6.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.